There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]
[13] [12] Individual response varies considerably based on baseline microbiome composition, diet, medications, and health status
Our Daily Replenisher and Daily Nutritional Supplement were designed for GLP-1 users, helping cover the nutrients most likely to dip and supporting sustained energy, muscle recovery, and overall metabolic health
Why Retatrutide Entered the Bodybuilding Conversation Retatrutide built its reputation on fat loss
Spotting Between Periods Light spotting or unexpected bleeding can sometimes happen during hormonal adjustments
The onset of Long COVID shares striking molecular similarities with ME/CFS, particularly regarding the catastrophic depletion of glutathione